Skip to content

Study · Animal study (in vivo) · drosophila · 2013

2 results

NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.

Quraishe S, Cowan CM, Mudher A

Molecular psychiatry16 Apr 2013Cited by 65 (Europe PMC)

PMID23587881 (opens in a new tab)PMCIDPMC3690421 (opens in a new tab)DOI10.1038/mp.2013.32 (opens in a new tab)PepBankPUB-23587881
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a Drosophila tauopathy model, NAP prevented and reversed established neuronal dysfunction phenotypes.

    In plain wordsIn Drosophila, NAP prevented and reversed neuronal problems in a tauopathy model.

    Peptide
    Davunetide
    Outcome
    DecreaseTau-mediated neuronal dysfunction phenotypes
    Study

    Drosophilan: not reported in source

    human tau tauopathy model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that a microtubule-stabilising drug, NAPVSIPQ (NAP), prevents as well as reverses these phenotypes even after they have become established.
    1 context sentence
    Summary · context
    We have developed a Drosophila model of tauopathy in which abnormal human tau mediates neuronal dysfunction characterised by microtubule destabilisation, axonal transport disruption, synaptic defects and behavioural impairments.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In a Drosophila tauopathy model, NAP did not alter abnormal tau levels.

    In plain wordsIn Drosophila, NAP did not change abnormal tau levels.

    Peptide
    Davunetide
    Outcome
    No significant changeAbnormal tau levels
    Study

    Drosophilan: not reported in source

    human tau tauopathy model
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, it does not alter abnormal tau levels indicating that it by-passes toxic tau altogether.
    1 context sentence
    Summary · context
    We have developed a Drosophila model of tauopathy in which abnormal human tau mediates neuronal dysfunction characterised by microtubule destabilisation, axonal transport disruption, synaptic defects and behavioural impairments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.